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NOTCH1,which is frequently mutated in T cell acute lymphoblastic leukemia, has been an elusive therapeutic
target. In this issue of Cancer Cell, Roti and colleagues demonstrate that inhibiting SERCA calcium pumps
preferentially impairs the maturation of the most common class of oncogenic Notch1 mutants, thus uncov-
ering a potential therapeutic avenue.The four mammalian Notch receptors are
large type I membrane proteins, sporting
an extracellular domain with 29–36
epidermal growth factor (EGF) repeats
followed by the conserved Lin12-Notch
repeats (LNR) and a heterodimerization
domain (HD; Figure 1A). The LNR and
HD domains constitute the negative
regulatory region (NRR), which maintains
the ‘‘off’’ state of the receptor in the
absence of ligand. Upon binding of Notch
to ligand presented by a neighboring cell,
the NRR undergoes a conformational
change to expose the S2 site to ADAM
metalloprotease cleavage (Figure 1B).
This is followed by g-secretase-mediated
cleavage at the S3 site within the trans-
membrane domain (TMD), which releases
the Notch intracellular domain (NICD).
NICD translocates to the nucleus,
associates with the DNA-binding protein
RBPjk and the transcriptional coactivator
Mastermind (MAM/MAML) to activate
transcription. Activation is linked to phos-
phorylation of the PEST domain, its
recognition and ubiquitination by the E3
ubiquitin ligase FBW7, and NICD degra-
dation (reviewed in Kopan and Ilagan,
2009).Because the Notch signaling pathway
regulates many fundamental processes
during embryonic development and in
self-renewing adult tissues, both gain-
and loss-of-function mutations in path-
way components lead to developmental
disorders, cancer, and other adult onset
diseases. Best known is the contribution
of ligand-independent, activated forms
of Notch1 to T-ALL, more than half of
which gain activating mutations in the
NRR, PEST, or both (Figure 1A; Weng
et al., 2004). The mutations in the NRR
lead to ligand hypersensitivity and
ligand-independent activation, whereas
the PEST domain mutations increase the
stability of NICD and lead to sustained
signaling activity.
The preponderance of NOTCH1 muta-
tions in T-ALL has fueled the search
for effective anti-Notch1 therapeutics
(Figure 1B; reviewed in Tzoneva and
Ferrando, 2012). Because Notch activa-
tion relies on proteolysis, g-secretase
inhibitors (GSIs), which had been origi-
nally developed for Alzheimer’s disease
therapy, have entered clinical trials for
treatment of relapsing T-ALL. However,
sustained GSI inhibition is not tolerated,because pan-Notch blockade causes
severe gastrointestinal toxicity and
promotes progression of squamous cell
carcinomas (Extance, 2010). The same
problems could affect the efficacy of
stapled dominant negative MAML-like
peptides (SAHM) that directly target the
transcription complex. More recently,
receptor-specific anti-NRR1 antibodies
have been developed. Despite their ability
to circumvent gut toxicity, sustained
treatment with these reagents will likely
cause vascular neoplasms, raising addi-
tional safety concerns (Yan et al., 2010).
To identify modulators of Notch1 sig-
naling and potential therapeutic targets
for T-ALL, Roti et al. (2013; in this issue
of Cancer Cell) conducted complemen-
tary high throughput small molecule
and cDNA overexpression screens using
cell-based assays reporting Notch tran-
scriptional activity. For the compound
screen, the transcriptional signature of
Notch in T-ALL was assembled from
previous genome-wide expression pro-
filing studies of multiple human T-ALL
cell lines treated with vehicle or GSI.
They validated a group of 28 target and
4 nontarget genes to generate a robust,3, March 18, 2013 ª2013 Elsevier Inc. 267
Figure 1. The Core Notch Signaling Pathway and Strategies for Therapeutic Intervention
(A) Domain organization of Notch1 (RAM, RBPjk-association module; ANK, ankyrin repeats; PEST,
proline/glutamic acid/serine/threonine degron domain). Cleavage sites for furin (S1), ADAM metallopro-
tease (S2), and g-secretase (S3) are indicated. The NRR keeps the receptor ‘‘off’’ in the absence of ligand.
Gain-of-function mutations associated with T-ALL (highlighted in red) predominantly lie within HD, which
lead to ligand hypersensitivity and ligand-independent activation, or within PEST, which typically lead to
deletions and truncations and therefore increased stability and prolonged signaling activity. HD and PEST
activating mutations can also occur in cis. Notably, loss-of-function mutations throughout the entire
coding region are also associated with cancer, most often in head and neck squamous cell carcinoma.
(B) Core Notch signaling pathway. The Notch receptor is processed at cleavage site 1 (S1) by furin-like
proteases in the Golgi and is expressed at the cell surface as an intramolecular heterodimer held together
via interactions between the N- and C-terminal regions of HD. Upon ligand binding, Notch is sequentially
cleaved by ADAM and by g-secretase, thereby releasing NICD to activate transcription. Notch T-ALL
mutants (HD mutant with DPEST shown) exhibits ligand-independent receptor activation. Various
aspects of the Notch signaling mechanism can be targeted for therapeutic intervention; a-NRR1
antibodies stabilize the auto-inhibited conformation of NRR to prevent S2 cleavage; GSIs prevent
cleavage and NICD release, SAHM peptides block transactivation complex function. All these modes of
inhibition target wild-type and mutant receptors similarly. SERCA inhibition by thapsigargin (TG) selec-
tively targets the maturation and activity of mutant Notch receptors carrying the most common type of
HD mutations found in T-ALL (class I).
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Previewshighly predictive, and Notch-dependent
gene expression signature. Three thou-
sand eight hundred one drugs and drug-
like molecules were screened against
a human T-ALL cell line (DND41), which
carries an activating mutation in the HD
of Notch1 alongwith a PEST domain dele-
tion (L1594PDPEST). In parallel, they also
screened a cDNA expression library of
18,000 open reading frames to identify
gene products that would enhance the
activation of a transcriptional reporter
downstream of another mutant Notch1268 Cancer Cell 23, March 18, 2013 ª2013 Ereceptor identified in T-ALL patients
(L1601PDPEST) expressed in the U2OS
osteosarcoma cell line. The selection of
NRR mutants in both screens proved to
be a fortuitous decision.
Perhaps surprisingly, calcium modula-
tors emerged as hits in both the com-
pound and cDNA screens. One of the
top compound hits was thapsigargicin,
an analog of thapsigargin, which is a
potent natural product inhibitor of sarco/
endoplasmic reticulum Ca2+-ATPase
(SERCA). Among the top cDNA hitslsevier Inc.were ATP2A1, ATP2A2, and ATP2A3,
which encode SERCA1, SERCA2, and
SERCA3, respectively. SERCAs use
ATP to pump Ca2+ from the cytoplasm
to the internal stores. Notably, previous
studies in Drosophila identified the
SERCA homolog, Ca-P60A, as a modu-
lator of Notch transport and activity
(Periz and Fortini, 1999). However, the
loss of all SERCA activity in Drosophila
demonstrated a general requirement for
Ca2+-ATPase for all membrane protein
trafficking, which would predict a plethora
of untoward effects with SERCA modula-
tion akin to the problems experienced
with GSI. This proved not to be the case
at low inhibitor concentration.
Because the EGF and LNR domains of
Notch all require Ca2+ for proper protein
folding and exit from ER, Roti et al.
(2013) hypothesized that SERCA inhibi-
tion was affecting the maturation process
of Notch1. Indeed, thapsigargin treat-
ment reduced the level of furin process-
ing, a step that occurs in the trans-Golgi
during transport of Notch proteins. Mis-
folded full-length receptors were retained
in the ER/Golgi compartment, leading to
diminished levels at the cell surface.
Consistent with effects related to the
Ca2+-binding modules, constitutively
active forms of Notch1 lacking the EGF
and LNR domains were refractory to
effects of thapsigargin. In addition,
expression of NICD can rescue the nega-
tive effects of thapsigargin on the cell
cycle, cell size, and cell viability of
T-ALL lines in vitro and in a xenograft
model.
Although the functional assays in flies
(Periz and Fortini, 1999; Roti et al., 2013)
clearly show that wild-type Notch function
can be modulated by SERCA inhibition,
the decision to screen against NRR
mutants provided a critical observation;
the Notch1 mutational status affected
the efficacy of thapsigargin. Thapsigargin
had a stronger effect on molecules con-
taining the class I HD mutations, which
encompass point substitutions and small
in-frame insertions or deletions in HD
and are the most common type of acti-
vating Notch1 mutants in T-ALL (Malecki
et al., 2006). At thapsigargin concentra-
tions that did not inhibit signaling from
wild-type Notch1 and Notch2 receptors,
signaling from the Notch1 receptor
carrying the L1601PDPEST leukemogenic
mutation was impaired. Cell cycle and
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Previewscell viability were more strongly affected
by thapsigargin in T-ALL lines with HD
mutations in Notch1 than those carrying
wild-type Notch1. Moreover, significant
on-target antileukemia effects with no
gastrointestinal toxicity were observed in
two independent human T-ALL xenograft
models carrying HD mutations. The lack
of gut toxicity indicates that sufficient
levels of wild-type Notch1 and Notch2
receptors reached the surface in the
presence of SERCA inhibitors, whereas
oncogenic Notch molecules were selec-
tively and effectively prevented from
exiting the ER.
Why would SERCA inhibition preferen-
tially affect the maturation and activity of
mutant receptors? Roti et al. (2013) spec-
ulate that the reason may reflect folding
defects in many of the activating HD
mutations identified in T-ALL (Malecki
et al., 2006). SERCA inhibitors exploit
this impaired folding and block matu-
ration of the mutant receptor (Fig-
ure 1B). Alternatively or simultaneously,
the mutant Notch1 proteins themselves
trigger ER stress, making the cells more
sensitive to the increase in ER stressinduced by thapsigargin treatment,
leading to enhanced clearance of mutant
Notch proteins. Regardless of the under-
lying mechanism, these studies provide a
therapeutic window for targeting SERCA
as an antileukemia strategy for many
T-ALL patients harboring mutations in
the NRR.
While promising, many challenges
remain before translating this strategy to
the clinic. Given the fundamental role of
calcium in normal physiology and the
pleiotropic roles of Notch in tissue
maintenance and cancer suppression
(South et al., 2012), targeted delivery of
SERCA inhibitors to T-ALL cells would
be desirable. This was achieved with
delivery of modified thapsigargin to
human cancer xenografts (Denmeade
et al., 2012). Even if thapsigargin can be
specifically targeted, T-ALL may contain
cells refractory to treatment, having lost
the NRR or gained activating Myc muta-
tions. Perhaps the most beneficial use
for thapsigargin will be in combinatorial
therapies aimed to combat T-ALL at its
earliest manifestation before additional
mutations are gained.Cancer Cell 2REFERENCES
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WNT/b-catenin signaling is critical to the development of many cancer types. A paper by Mo and colleagues
in a recent issue of Cell shows that autocrine CXCL12/CXCR4 chemokine signaling activates b-catenin
signaling in a rare peripheral nerve sarcoma. Together with the availability of small molecules targeting
CXCR4, this finding suggests new avenues for cancer therapy.It is exciting to link established signaling
pathways. It is especially provocative
when compounds designed to targetone molecule for a specific disease are
shown to have potential in a novel
context. In a recent issue ofCell, the labo-ratories of Luis Parada and Lu Le accom-
plish just this by showing that a pathway
that was first identified as relevant to3, March 18, 2013 ª2013 Elsevier Inc. 269
